A study of potantial drug-drug interactions with linezolid in the intensive care unit: A retrospective study

The aim of this thesis is to provide information flow to stakeholders in clinical use by clarifying the possible interactions of the drug Linezolid with other drugs used during infection treatment in patients in intensive care units. In the study, data from the files of intensive care patients over the age of 18 who were hospitalized for at least 24 hours between 2017 and 2023 in the Intensive Care Unit of the Department of Anesthesiology and Reanimation, Süleyman Demirel Faculty of Medicine, and who used at least one different drug in addition to the active substance Linezolid during this period were used. These data were evaluated with the Lexi-Interact program. Included in the study, 68 (36%) patients were exposed to polypharmacy for 2-22 days, 69 (36.5%) patients for 23-45 days and 52 (27.5%) patients for 46-197 days. A total of 655 interactions were observed. Among these, type A interaction was 17 (8.99%), type B interaction was 172 (91%), type C interaction was 183 (96.83%), type D interaction was 184 (97.35%) and type X interaction was 99 (52.38%); 17.20%), type D interaction with Salbutamol (94; 49.70%) and type X interactions, which are not recommended to be used side by side with Linezolid, with Metoclopropamide (44; 23.30%) and Escitalopram (11; 5.80%). In conclusion, the potential drug-drug interactions detected with Linezolid can be interpreted as developing effects at a tolerable level by patients.